The estimated Net Worth of Kathryn B Mc Kenzie is at least $1.33 Million dollars as of 11 January 2022. Ms. Kenzie owns over 2,100 units of Neogenomics stock worth over $805,078 and over the last 7 years she sold NEO stock worth over $0. In addition, she makes $524,844 as Chief Financial Officer at Neogenomics.
Kathryn has made over 3 trades of the Neogenomics stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 2,100 units of NEO stock worth $19,047 on 11 January 2022.
The largest trade she's ever made was exercising 8,000 units of Neogenomics stock on 10 December 2019 worth over $64,240. On average, Kathryn trades about 1,678 units every 85 days since 2017. As of 11 January 2022 she still owns at least 49,361 units of Neogenomics stock.
You can see the complete history of Ms. Kenzie stock trades at the bottom of the page.
Kathryn B. McKenzie serves as Chief Financial Officer of the Company. Prior to this appointment she served as Vice President of Finance and Chief Accounting Officer since October 2017. She also served as the Company’s Principal Financial Officer since August 2019. Prior to joining the Company, Ms. McKenzie served at Chico’s FAS, Inc. in various roles including Assistant Controller and Director of Financial Reporting and Treasury. Ms. McKenzie also previously served as Audit Manager for Ernst and Young. Ms. McKenzie is a Certified Public Accountant and holds a Master’s of Science in Accountancy from the University of North Carolina Wilmington.
As the Chief Financial Officer of Neogenomics, the total compensation of Kathryn McKenzie at Neogenomics is $524,844. There are 6 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
Kathryn McKenzie is 35, she's been the Chief Financial Officer of Neogenomics since 2020. There are 26 older and no younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Kathryn's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van, and Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: